Engineering Longer-Lasting Somatostatin Peptide Analogs for Radioactive Cancer Treatment

Researchers designed and synthesized two JR11 peptide analogs incorporating albumin-binding domains. Both were radiolabeled with lutetium-177 and characterized for radiochemical purity and stability. In vitro assays measured albumin binding, SSTR2 affinity, cell uptake, and internalization. In vivo SPECT/CT imaging tracked tumor accumulation over 72 hours in tumor-bearing mice. Ex vivo biodistribution studies quantified organ-level uptake to assess therapeutic suitability.

Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors, but optimizing peptide pharmacokinetics remains critical. While longer blood circulation could increase radiation delivered to tumors, this study reveals the trade-off: extended circulation also increases radiation to healthy tissues. Finding the right balance is essential for making safer, more effective radioactive cancer treatments.

This study illustrates a common challenge in radiopharmaceutical development: modifying peptides to improve one property (blood residence time) can compromise others (receptor affinity, biodistribution). SSTR2-targeting peptides are already clinically successful (e.g., Lutathera/[177Lu]Lu-DOTATATE), and research into antagonist-based approaches like JR11 aims to improve tumor-to-background ratios. This work provides valuable data on albumin-binding strategies, even though the current analogs weren't therapeutically optimal.

Both analogs showed substantially reduced SSTR2 binding affinity compared to the parent peptide JR11, which may limit therapeutic efficacy. One analog (8b) showed no tumor uptake in vivo despite in vitro activity, highlighting the gap between bench and in vivo performance. The study was preclinical (mouse models only). The unfavorable biodistribution of 8a means neither analog is suitable for clinical development in its current form.